AEGIRBIO PRESENTATION AT ACTRIMS
Clinical data obtained using a newly developed assay confirms high correlation between saliva and blood for measurement of Natalizumab (Tysabri) as well as the hypothesis that transformation of the drug in to less potent form varies between individuals.Natalizumab is highly effective at improving outcomes in people with active relapsing-remitting multiple sclerosis. Once administered, natalizumab can transform to a less potent form but the extent to which this occurs varies between individuals. At ACTRIMS 2023, AegirBio presented clinical data obtained using newly developed assays that